Investigators from Laboratory of Ultrastructure Have Reported New Data on Obesity and Diabetes (Semaglutide Attenuates Anxious and Depressive-like Behaviors and Reverses the Cognitive Impairment In a Type 2 Diabetes Mellitus Mouse Model Via the...).

A recent study conducted in Recife, Brazil suggests that metabolic disorders such as diabetes and obesity may be significant risk factors for psychiatric disorders. The researchers propose that drugs originally developed to treat antidiabetic conditions could potentially be repurposed as novel antidepressant medications. The study focused on a mouse model of depression linked to type 2 diabetes induced by a high-fat diet, and found that the drug semaglutide effectively mitigated depressive and anxiety-like behaviors, improved cognitive function, and protected synaptic plasticity. The researchers concluded that semaglutide has the potential to be a therapeutic tool for depression and anxiety. [Extracted from the article]